Company news
Tiziana Life Sciences Ltd news in 2022
Tiziana Life Sciences Ltd's news releases, calls and decks from 2022, newest first.
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022
December 26, 2022
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
December 14, 2022
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements
December 13, 2022
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
December 5, 2022
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects
November 22, 2022
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)
November 9, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
November 2, 2022
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
November 1, 2022
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
October 25, 2022
Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients
October 11, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 28, 2022
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
September 27, 2022
Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab
September 19, 2022
Tiziana Life Sciences Announces Grant received by the Brigham and Women’s Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis
September 14, 2022
Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease
July 31, 2022
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer
July 17, 2022
Tiziana Life Sciences Announces Resignation of CEO
July 14, 2022
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
June 7, 2022
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
May 23, 2022
FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab
April 4, 2022
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
March 24, 2022
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
March 9, 2022
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease
February 3, 2022
Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million
January 23, 2022
Tiziana Life Sciences Announces Death of Director
January 12, 2022
Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis
January 9, 2022
Decks in 2022
- Investor Presentation (October 2022)
Investor deck · 28 slides · Oct 25, 2022